A lightweight, gel-free and waterproof wearable heart monitor developed from research at RMIT University has entered a clinical trial in Australia, as its developers look to build evidence toward potential regulatory approval.
The device, a wireless ECG patch being developed by start-up Lubdub, is designed to continuously track heart rhythm for up to 14 days. RMIT and Lubdub say it is intended to provide doctors with detailed information comparable to a medical-grade electrocardiogram (ECG) Holter monitor.
The trial is taking place at Midlands Medical Specialists in Perth, Western Australia, with patients who have been prescribed a Holter monitor also wearing the prototype patch.
RMIT Professor and Lubdub co-founder Sharath Sriram said the ECG patch is the first of three heart-monitoring technologies the company plans to integrate into a single software platform, alongside biomarker testing and wearable ultrasound imaging. RMIT has licensed the intellectual property for the ECG and biomarker inventions to Lubdub.
Sriram said earlier testing with healthy volunteers found the prototype comfortable and produced “promising results”. He attributed this to flexible sensors that he said made better contact with the skin than those used in traditional Holter monitors.
He said the patch produced data that was “18-times cleaner” than traditional Holter monitors and could reduce the work required to generate cardiac reports, potentially enabling the same workforce to monitor “up to 85% more patients” before tools such as AI are implemented.
Momentum builds
Sriram said the technology has attracted interest from clinicians because of its potential to reduce delays between symptoms and treatment, and to improve access to cardiac monitoring in metropolitan, rural and remote areas.
He cited cardiovascular disease as responsible for a third of deaths globally and nearly a quarter in Australia, and said early symptoms are often missed, with many diagnoses and admissions occurring in emergency settings.
The Heart Foundation named Lubdub as one of its 10 most promising heart health projects for 2026, according to the release.
Lubdub said it raised $6 million in an oversubscribed seed funding round announced in September, doubling its original $3 million target, with backing mainly from physicians and heart specialists.
Heart health in a box
Lubdub said it ultimately aims to combine wearable ECG monitoring, non-invasive cardiac biomarker testing and wearable ultrasound imaging into a single platform, arguing that diagnostic testing can be fragmented across multiple appointments, specialists and facilities.
Lubdub co-founder and director Nikhilesh Bappoo said the project was motivated in part by his father’s heart attack in Perth and a contrast with access to specialist care in Mauritius, where he grew up.
From research to commercialisation
Lubdub said its partnership with RMIT includes research grants and contracts, as well as access to pilot manufacturing facilities at Discovery to Device.
RMIT Deputy Vice-Chancellor Research and Innovation Distinguished Professor Calum Drummond AO said the licensing agreement with Lubdub was an example of university research being translated into products and practical benefits, and that RMIT would continue working with the company as it advances the technology toward regulatory approval.

